98%
921
2 minutes
20
Association between spatial gait parameters and adverse health outcomes in the elderly has not been sufficiently studied. The goal of this study is to evaluate whether the stride length or the step width predict falls, functional loss and mortality. We conducted a prospective cohort study on a probabilistic sample of 431 noninstitutionalized, older-than-64-years subjects living in Spain, who were followed-up for five years. In the baseline visit, spatial gait parameters were recorded along with several control variables, with special emphasis on known medical conditions, strength, balance and functional and cognitive capacities. In the follow-up calls, vital status, functional status and number of falls from last control were recorded. We found that a normalized-to-height stride length shorter than 0.52 predicted recurrent falls in the next 6 months with 93% sensitivity and 53% specificity (AUC: 0.72), and in the next 12 months with 81% sensitivity and 57% specificity (AUC: 0.67). A normalized stride length <0.5 predicted functional loss at 12 months with a sensitivity of 79.4% and specificity of 65.6% (AUC: 0.75). This predictive capacity remained independent after correcting for the rest of risk factors studied. Step-with was not clearly related to functional loss or falls. Both shorter normalized stride length (OR1.56; AUC: 0.62; p < 0.05) and larger step width (OR1.42; AUC: 0.62; p < 0.05) were associated with risk of death at 60 months; however, none of them remained as independent predictor of death, after correcting for other risk factors. In summary, spatial gait parameters may be risk markers for adverse outcomes in the elderly. Step length is independently associated with functional loss and falls at one year, after correction for numerous known risk factors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584504 | PMC |
http://dx.doi.org/10.1038/s41598-019-45113-2 | DOI Listing |
BMC Neurol
September 2025
Department of Neurology, University Hospital Schleswig-Holstein, Kiel, Germany.
Background: Parkinson's disease (PD) is characterized by motor symptoms altering gait domains such as slow walking speed, reduced step and stride length, and increased double support time. Gait disturbances occur in the early, mild to moderate, and advanced stages of the disease in both backward walking (BW) and forward walking (FW), but are more pronounced in BW. At this point, however, no information is available about BW performance and disease stages specified using the Hoehn and Yahr (H&Y) scale.
View Article and Find Full Text PDFJ Neuroeng Rehabil
September 2025
Institute for Neuromodulation and Neurotechnology, University Hospital and University of Tübingen, 72076, Tübingen, Germany.
Innovative technology allows for personalization of stimulation frequency in dual-site deep brain stimulation (DBS), offering promise for challenging symptoms in advanced Parkinson's disease (PD), particularly freezing of gait (FoG). Early results suggest that combining standard subthalamic nucleus (STN) stimulation with substantia nigra pars reticulata (SNr) stimulation may improve FoG outcomes. However, patient response and the optimal SNr stimulation frequency vary.
View Article and Find Full Text PDFClin Auton Res
September 2025
Department of Neurology, University of Arkansas for Medical Sciences, 4301 W. Markham St., #500, Little Rock, AR, 72205-7199, USA.
Purpose: Orthostatic hypotension (OH) is a non-motor feature in people with Parkinson's disease that can lead to falls from syncope. Current knowledge is lacking on the effects of OH on gait function.
Methods: Participants enrolled in a prospectively monitored longitudinal cohort who had OH on vitals at one of two consecutive visits approximately 6 months apart were analyzed.
Biomater Adv
September 2025
Department of Anesthesiology, Ganzhou Key Laboratory of Anesthesiology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China. Electronic address:
Spinal cord injury (SCI) is exacerbated by the formation of an acidic microenvironment and extensive neuronal loss, both of which contribute to poor functional recovery. To address this, we developed lysine-polydopamine nanoparticles (Lys-PDA) as a multifunctional therapeutic platform for SCI. Lysine, a naturally occurring amino acid, possesses weak alkalinity and neuroprotective properties, but suffers from poor in vivo stability and non-specific distribution.
View Article and Find Full Text PDFFront Neurol
August 2025
Department of Neurology, Central Hospital of Dalian University of Technology, Dalian, China.
Background: Gait disorder is one of the clinical manifestations of Parkinson's disease (PD). Investigating the characteristics of gait disorder in patients with PD and the changes in gait before and after taking levodopa is crucial for the recognition, diagnosis and treatment of gait disorders in PD patients.
Methods: In this study, we measured the gait parameters of 20 patients with PD and 17 healthy controls and analyzed the changes of gait parameters of these patients before and after taking levodopa.